This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 1 mg QD from lamivudine versus maintaining lamivudine 100 mg QD treatment in HBV-infected subjects currently receiving lamivudine monotherapy.
Name: Entecavir
Description: entecavir 1.0 mg QDType: DrugA
Name: Lamivudine
Description: lamivudine 100 mg QDType: DrugB
Allocation: Randomized
Parallel Assignment
There is one SNP
Exclusion Criteria: - All subjects will be tested for presence of M204V/I mutations in the YMDD motif at baseline. --- M204V ---
Subjects with M204V/I mutations in the YMDD motif at baseline are not eligible for the study. --- M204V ---